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TO THE EDITOR
Correct classification of leukemia and lymphoma forms is essential for the selection of effective therapies. Traditionally, classification relied on cytology, but, increasingly, molecular characteristics of tumor cells are being utilized for diagnosis. Also, measurement of soluble products released by tumor cells provides a comparatively easy and reliable method to monitor tumor progression and/or efficacy of therapy.
CD137 is a member of the TNF receptor family and a potent T-cell costimulatory molecule. Soluble forms of CD137 (sCD137) are generated by differential splicing and are released by activated T cells, predominantly at a high activation stage.
1,2
Soluble CD137 is antagonistic to the costimulatory activities of the membrane-bound CD137 and reduces immune activity. 3, 4 Levels of sCD137 are detectable at elevated concentrations in sera of autoimmune patients indicating its participation in a negative feedback regulation of immune responses.
1, 5, 6 In this study we demonstrate for the first time that sCD137 can also be detected at enhanced levels in sera of leukemia and lymphoma patients, and that enhanced levels of sCD137 are strongly associated with chronic lymphocytic leukemia (CLL).
Base line levels of sCD137 were determined in sera of 120 healthy donors by ELISA.
1 These control sera had a mean of 0.17 ng/ml and a standard deviation of 0.18 ng/ml of sCD137. The median and the 25 and 75% percentile were 0.1, 0 and 0.15 ng/ml, respectively. Individual sera were classified as positive if their sCD137 concentration was above that of mean þ 2 s.d. of control sera, that is, 0.53 ng/ml. Only three of the 120 control sera with sCD137 concentrations of 0.6, 0.6 and 0.7 ng/ml, respectively, were accordingly classified as positive.
The sera of 173 patients with different hematological malignancies had significantly higher sCD137 concentrations. The mean and maximum sCD137 concentrations of the entire patient collective were 0.58 and 4.4 ng/ml, respectively, compared to 0.18 and 0.7 ng/ml, respectively, for healthy donors (Table 1 ). In addition, 17.3% of the patient sera contained sCD137 above the 0.53 ng/ml positivity threshold while only 2.5% of control sera were positive for sCD137.
Positive sera were found in most disease groups (Figure 1 ). However, for most leukemias and lymphomas the percentage of positive sera was around or below 10% (Table 1 ). The exception was Non-Hodgkin's lymphoma (NHL) where 24 out of 106 (22.6%) sera were positive for sCD137. NHL sera also contained the highest concentrations of sCD137 with a mean of 0.65 ng/ml (Table 1) . Myeloproliferative syndrome (MPS) had a similar high percentage of positive sera (20%), but this number may not be reliable due to the few samples (n ¼ 5).
NHL comprises a variety of diverse lymphoma subgroups. We therefore analyzed expression of sCD137 in NHL subtypes.
With 11 out of 14 (78.6%), CLL was the subgroup with by far the highest frequency of positive sera (Figure 1) . Also, CLL sera contained the highest concentration of sCD137 with a mean and an STD of 1.16 and 1.14 ng/ml, respectively, and the single highest value of 4.4 ng/ml (Table 1 ). In fact, the increased sCD137 values of NHL in terms of frequency and mean could be attributed predominantly to the CLL subgroup.
Sera in which no sCD137 could be detected were frequent or prevalent in all other leukemias and lymphomas, except CLL (Figure 1 ). Soluble CD137 was detectable in all of the 14 CLL sera, though three contained less than 0.53 ng/ml and were therefore classified as negative. CLL was the leukemia form that had the strongest association with elevated sCD137 levels in all categories analyzed.
The other NHL subgroup with enhanced sCD137 sera levels was immunocytoma. Four out of 20 (20%) immunocytoma sera were positive and the mean of 0.74 ng/ml was clearly above the 0.53 ng/ml positivity threshold. CLL and immunocytoma share many common characteristics and are often not easy to distinguish. 7 These similarities may also be the basis for their increased sCD137 levels. Leukemias and lymphomas were classified according to the Kiel classification. 8 Soluble CD137 is not selective for a specific disease, because it can be detected at enhanced levels and frequencies in most leukemia and lymphoma forms. Elevated levels of sCD137 can also be found in sera of patients with rheumatoid arthritis, multiple sclerosis and systemic lupus erythematousus and Behcet's disease.
1,5,6 Therefore, enhanced levels of sCD137 may rather be reflective of a specific immune activation stage. It has been demonstrated in vitro that sCD137 is produced exclusively by highly activated T cells, and that sCD137 release does not correlate with proliferation, but rather with activation induced cell death. This implies that sCD137 forms a negative feedback loop to reduce further activation through membrane-bound CD137 and to prevent activation induced cell death. 2 In that case, enhanced sCD137 levels in tumor patient sera could be a sign of an active antitumor immune response.
However, it cannot be excluded that sCD137 is produced by the malignant cells. As costimulation of lymphocytes through cell surface CD137 enhances lymphocyte activation, and because sCD137 is antagonistic, tumor cells could produce sCD137 as a neoantigen in order to quench an antitumor immune response. sCD137 would then be an additional immunoregulatory molecule, besides CD95 ligand or TGF-b, which can be expressed ectopically by tumors in order to evade immune surveillance. However, regardless of whether sCD137 is produced by the tumor cells or by antitumor T cells, it is in both cases expected to inhibit an antitumor immune response, and therefore removal of sCD137 from the serum may enhance the antitumor immunity.
The questions that remain topics for future studies are why sCD137 is present in only a proportion of patients, and whether sCD137 levels correlate with other parameters, such as disease stage, progression or therapeutic success. Longitudinal studies may identify whether sCD137 is useful as a prognostic or diagnostic marker. Due to the strong association of enhanced sCD137 concentrations and frequencies with CLL, this leukemia may be best suited for such studies. 
Figure 1
Soluble CD137 levels are enhanced in sera of patients with hematological malignancies. Each point represents the sCD137 value of one serum. The numbers in parentheses at the x-axis give the numbers of sera in which no sCD137 could be detected. Short horizontal bars indicate the mean value. The stippled horizontal lines represent the positivity threshold value of 0.53 ng/ml. P-values were calculated using a onetailed t-test with the assumption of equal variances between groups. ALL: acute lymphoid lymphoma; AML: acute myeloid lymphoma; cc: centrocytic; cb: centroblastic; CML: chronic myeloid lymphoma; CLL: chronic lymphocytic lymphoma; HD: Hodgkin's disease; IC: immunocytoma; MDS: myelodisplastic syndrome; MPS: myeloproliferative syndrome; PC: plasmocytoma. The majority of patients with acute myeloid leukemia (AML) achieve complete remission after induction and consolidation therapy. However, a significant proportion of patients eventually relapse and die from their disease. Early detection of minimal residual disease (MRD) may offer the possibility of implementing salvage therapies prior to overt clinical relapse. It is still not entirely clear, however, how to deal with the molecular relapse therapeutically nor how to monitor it.
1
For technical reasons, MRD monitoring is considered especially for patients who suffer from AML with recurrent genetic abnormalities. Acute promyelocytic leukemia with t(15;17) now differs from other AML subtypes, thanks to an effective and tailored therapeutic approach. Further welldefined leukemias considered for MRD monitoring using the quantitative-PCR method are those with t(8;21), inv(16), or t(16;16), and 11q23 abnormalities.
2-5 Frequent MRD monitoring of patients with these forms of AMLs could help to answer the following important questions: (1) How does the MRD behave between the cycles of chemotherapy in AML? (2) How long is the period between the molecular and hematological relapse? (3) Is it possible to increase the success rate of AML therapy by treating the molecular relapse as opposed to treatment begun at the moment of clear hematological relapse?
In an effort to answer these questions, we have performed a pilot study in nine patients (125 specimens, 14 on average in one patient) with the AML with t(8;21), inv(16), and 11q23 abnormalities. We regularly monitored the fusion transcripts AML1/ETO, CBFb/MYH11, and MLL genes using quantitative real-time polymerase chain reaction (RQ-RT-PCR; the expression of the fusion gene to the expression of the housekeeping gene ABL). The specimens of bone marrow and/or peripheral blood were collected before beginning therapy and later in approximately monthly intervals. Molecular genetic examination was correlated with the results of cytogenetic and morphological studies. Molecular relapse (confirmed by repeated examination) was defined as the reappearance of positivity after a previous negative result or as an at least 10-fold rise in positivity.
The results are shown in Table 1 . In patient no. 1, 2, 3, 5, 6, and 8, we observed isolated molecular relapse of the disease (not accompanied by cytogenetic or morphological abnormalities). It seems that patients who do not achieve stable complete molecular remission have a greater probability of suffering from hematological relapse. We did not observe a spontaneous disappearance of the MRD positivity. Unfortunately, to achieve the so-called complete molecular remission is not a definitive guarantee for long-term hematological remission. These patients can also relapse (patient no. 1, 3, 6, 7, and 8). The time period between the molecular relapse and hematological relapse is extremely variable. For example, in patient no. 5, molecular relapse preceded the hematological relapse by 6 months. However, on the other hand, in patient no. 7, fulminate relapse occurred despite being in molecular remission 1 month earlier.
After analyzing the period observed between the first molecular relapse and the following hematological relapse, in patient no. 1, we decided on chemotherapy of the second molecular relapse because of increasing dynamics of the MRD level. The patient was fully informed about the therapy and a written consent was given. Chemotherapy was later administered for similar reasons in patient no. 3 and 6. We used combinations of cytosine arabinoside (100 mg/m 2 /day) and daunorubicin or mitoxantrone. In patient no. 1 and 3, only a decrease in the level of MRD was observed; molecular remission had not been achieved. The decrease was greater than one order in magnitude and we called it a partial molecular response. In patient no. 6, however, the second complete molecular remission was achieved after only one course of chemotherapy, although dysplastic features in the bone marrow appeared. Unfortunately, 4 months after final chemotherapy, this patient developed a second molecular relapse. Moreover, chemotherapy also appeared ineffective in the treatment of MRD in patient no. 2, in whom there had been a rise in the quantity of MRD after the second and third consolidations with high-dose cytosine arabinoside during the first-line treatment of her disease. To the best of our knowledge, this is the first information about chemotherapy of molecular relapse of AMLs with CBFb/MYH11 and AML1/ETO fusion transcripts.
So far there are many ambiguities concerning the follow-up of the residual disease using quantitative RQ-RT-PCR in the AMLs with recurrent genetic abnormalities. The prognostic impact of the detection of CBFb/MYH11 or AML1/ETO transcripts in complete remission of AML as yet has not been clarified. 6 Studies of small groups with AML1/ETO 5 or CBFb/MYH11 2 AML identified tentative quantitative cutoff levels for good-vs poorrisk patients after consolidation therapy, but did not find an association between pretreatment or preconsolidation fusion
